Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sangamo Looks Forward After Shire Returns Hemophilia Rights

This article was originally published in Scrip

Executive Summary

Sangamo Biosciences touted the progress of its in vivo protein replacement platform (IVPRP) as it reported that Shire relinquished its rights to hemophilia programs under the companies' three-year-old collaboration, but investors were wary about the loss of an important alliance for two out or four partnered programs as well as the exchange of milestone fees for total control of preclinical assets.

You may also be interested in...



Gilead Partners With Sangamo For Gene Editing As It Builds Up Kite's Cell Therapy Platform

Gilead committed more than $3bn via its subsidiary Kite to license Sangamo's zinc finger technology for gene editing that may deliver improved T cell therapies for cancer. More deals are expected in this space as Gilead builds its cell therapy platform after buying Kite last year.

Biogen Shores Up Gene Therapy Ambitions With New Deal

Biogen Inc. has furthered its gene therapy ambitions by entering into a broad alliance with the University of Pennsylvania that could see it paying out up to $2bn in research funding and other payments. Biogen has made a series of moves over the past couple of years to build up its gene therapy research.

Asia Deal Watch: invoX Builds Novel Pipeline Through $161m F-star Acquisition

F-star's novel bispecific technology attracts Sino Biopharma-affiliated acquisition, Shionogi agreement with GARDP brings antibiotic cefiderocol to 135 countries, deal with WinHealth covering Greater China expands Quoin’s licensing of Netherton syndrome candidate to 60 nations, Kyorin and CellGenTech team up in Fabry disease.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC029665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel